Shopping Cart
Remove All
Your shopping cart is currently empty
Clamikalant sodium
🥰Excellent
Catalog No. T63330Cas No. 261717-22-0
Alias HMR1098, HMR 1098
Clamikalant sodium (HMR 1098) is an ATP-dependent potassium channel (KATP) cardiac-selective blocker, used in the study of arrhythmias.
Clamikalant sodium
🥰Excellent
Purity: 99.95%
Catalog No. T63330Alias HMR1098, HMR 1098Cas No. 261717-22-0
Clamikalant sodium (HMR 1098) is an ATP-dependent potassium channel (KATP) cardiac-selective blocker, used in the study of arrhythmias.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $39 | - | In Stock | |
| 5 mg | $89 | - | In Stock | |
| 10 mg | $176 | - | In Stock | |
| 25 mg | $355 | - | In Stock | |
| 50 mg | $569 | - | In Stock | |
| 100 mg | $892 | - | In Stock | |
| 200 mg | $1,220 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.95%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | Clamikalant sodium (HMR 1098) is an ATP-dependent potassium channel (KATP) cardiac-selective blocker, used in the study of arrhythmias. |
| Targets&IC50 | sK (ATP):0.36 mM |
| In vitro | Clamikalant sodium is a selective sarcosine K (ATP) channel inhibitor. It blocks the sK (ATP) current (IC (50) =0.36 mM) induced by the K (ATP) opener pinacidil. [1] In mouse atrial myocytes, both spontaneous activation and diazine-activated K (ATP) currents were effectively inhibited by 10 μM Clamikalant sodium. In contrast, in ventricular myocytes, high concentrations of Clamikalant sodium (100 μM) inhibited the K (ATP) current activated by the pinate, but low concentrations (10 μM) did not. Consistent with this finding, in COSm6 cells, Clamikalant sodium inhibits (86) Rb (+) efflux through Kir6.2/SUR1 more effectively than the Kir6.2/SUR2A channel. [2] |
| In vivo | Clamikalant sodium treatment (3 mg/kg push followed by continuous intravenous injection at 17 μg/kg/min throughout the study) did not prevent the shortening of HRA-ERP and the flattening or inversion of ERP rate adaptation in dogs. [3] |
| Synonyms | HMR1098, HMR 1098 |
| Molecular Weight | 493.96 |
| Formula | C19H21ClN3NaO5S2 |
| Cas No. | 261717-22-0 |
| Smiles | O=C(C1=CC(Cl)=CC=C1OC)NCCC2=CC=C(C(S(=O)([N-]C(NC)=S)=O)=C2)OC.[Na+] |
Storage & Solubility Information
| Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (80.98 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.05 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Clamikalant sodium | purchase Clamikalant sodium | Clamikalant sodium cost | order Clamikalant sodium | Clamikalant sodium chemical structure | Clamikalant sodium in vivo | Clamikalant sodium in vitro | Clamikalant sodium formula | Clamikalant sodium molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.